ESMO Real World Data & Digital Oncology | Publication | Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors
Our joint study on cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors has been published in ESMO Real World Data and Digital Oncology.
We harmonized data from three different EHR systems into three tumor-agnostic OMOP-CDM datasets, all carefully curated and enriched with cutting-edge clinical NLP.
Authors: Danielle Delombaerde, Clara L. Oeste, Vincent Geldhof, Lieselot Croes, Iege Bassez, Annelies Verbiest, Laura Tack, Dries Hens, Constantijn Franssen, Philip Debruyne, Hans Prenen, Marc Peeters, Johan De Sutter, Christof Vulsteke
This research is the first to use natural language processing (NLP) to enrich the detection of cardiovascular events from unstructured hospital data, offering novel insights into cardio-oncology.
Immune checkpoint inhibitors have been associated with diverse cardiovascular (CV) adverse events (AEs), yet their baseline prevalence and incidence following ICI initiation remain poorly understood. Using real-world data from Belgian hospitals, we aimed to bridge this gap.
Key findings:
• 12.5% incidence of CV events among ICI-treated patients - higher than clinical trials but consistent with other real-world studies.
• Longer time to onset compared to prior studies - emphasizing the need for long-term monitoring.
• Complex presentation of CV events highlights the importance of ongoing vigilance in clinical practice.
Thank you to the oncologists of AZ Maria Middelares, UZA and AZ Groeninge for collaboratively driving data standardization.
This research is the first to use natural language processing (NLP) to enrich the detection of cardiovascular events from unstructured hospital data, offering novel insights into cardio-oncology.
Immune checkpoint inhibitors have been associated with diverse cardiovascular (CV) adverse events (AEs), yet their baseline prevalence and incidence following ICI initiation remain poorly understood. Using real-world data from Belgian hospitals, we aimed to bridge this gap.
Key findings:
• 12.5% incidence of CV events among ICI-treated patients - higher than clinical trials but consistent with other real-world studies.
• Longer time to onset compared to prior studies - emphasizing the need for long-term monitoring.
• Complex presentation of CV events highlights the importance of ongoing vigilance in clinical practice.
Thank you to the oncologists of AZ Maria Middelares, UZA and AZ Groeninge for collaboratively driving data standardization.
